Pinho, Sandra http://orcid.org/0000-0002-5241-7364
Wei, Qiaozhi http://orcid.org/0000-0003-3062-5071
Maryanovich, Maria
Zhang, Dachuan
BalandrĂ¡n, Juan Carlos http://orcid.org/0000-0003-1978-248X
Pierce, Halley
Nakahara, Fumio http://orcid.org/0000-0003-1515-8284
Di Staulo, Anna
Bartholdy, Boris A.
Xu, Jianing
Borger, Daniel K.
Verma, Amit http://orcid.org/0000-0001-7592-7693
Frenette, Paul S. http://orcid.org/0000-0003-0862-9922
Funding for this research was provided by:
New York Stem Cell Foundation (Druckenmiller Fellowship)
Cancer Center, University of Illinois Cancer Biology Targeted Grant
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK056638)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL116340)
Leukemia and Lymphoma Society (LLS-TRP 6475-15)
New York State Department of Health (NYSTEM IIRP C029570, C029154)
Article History
Received: 30 December 2020
Accepted: 13 January 2022
First Online: 24 February 2022
Competing interests
: S.P., Q.W. and P.S.F. are co-inventors on a patent application using anti-VCAM1 antibodies (patent W02017205560A1). P.S.F. serves as a consultant for Pfizer, has received research funding from Ironwood Pharmaceuticals and is a shareholder of Cygnal Therapeutics. The remaining authors declare no competing interests.